Clinical Trial Update: TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TR-701 (tedizolid phosphate) to linezolid for acute bacterial skin and skin structure infections has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin and Subcutaneous Tissue Bacterial Infections

Drugs mentioned

• Linezolid (Linezolid)
• TR-701

Snippet

Sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Skin and Subcutaneous Tissue Bacterial Infections | Phase 3 | Status: COMPLETED | Results posted: 2014-09-08